Merck & Co has announced its agreement to acquire privately held Tilos Therapeutics for up to $773 million, bolstering its pipeline of drugs to treat cancer and autoimmune diseases. The deal includes an upfront payment and contingent milestone payments but the details of which have not been made public as of this writing. Massachusetts based Tilos was founded in part by the  Boehringer Ingelheim Venture Fund based on discoveries by the laboratory of Dr. Howard Weiner at Brigham and Women’s Hospital and Harvard Medical School. Learn More